Core Viewpoint - Zentek Ltd. has received a favorable judgment from the Ontario Superior Court, dismissing claims originally exceeding $6 million against the company, which marks a significant legal victory for Zentek [1]. Background - The litigation stemmed from the removal of Aubrey Eveleigh, the company's founder and former CEO, by shareholders during a special meeting on May 11, 2018 [1]. - Two companion actions were tried together in court, focusing on claims made by Mr. Eveleigh and his consulting firm [1]. Outcome - The court dismissed nearly all claims made by Mr. Eveleigh, including: - A Success Fee claim of $282,500, denied due to the lack of a pre-feasibility study [1]. - Severance claims totaling $1,350,000, found void and unenforceable due to breaches of fiduciary duty [1]. - Unpaid wages of $51,748.82, denied [1]. - Defamation damages of $75,000, denied as the statements were deemed factually accurate [1]. - Indemnification claims of approximately $194,000, denied [1]. - Zentek's claim for the cancellation of 4.5 million founder shares was upheld, with the court confirming the shares were properly issued [1]. CEO Comment - The CEO of Zentek, Moe Jiwan, stated that the judgment concludes a significant chapter in the company's history and emphasized the importance of focusing on execution in various projects moving forward [1]. Company Overview - Zentek Ltd. is a Canadian intellectual property development and commercialization company that focuses on graphene-enabled and advanced material technologies, particularly in clean air, next-generation materials, and critical minerals [1].

Core Insights - Zentek Ltd. provided an update on its activities at the PDAC 2026 Convention, focusing on government and First Nations engagement regarding the Albany Graphite Project [1] Government Engagement - The company participated in the TSX Canadian Mining Roundtable on March 2, 2026, discussing Canada's critical minerals strategy and the importance of domestic projects for NATO-aligned supply chains [1] - Albany Graphite's nuclear-grade purity and its location in Northern Ontario were highlighted during discussions with federal government representatives and Invest Ontario [1] - The company is advancing Albany's positioning within federal and provincial critical minerals funding frameworks, consistent with its government engagement strategy outlined in a previous news release [1] First Nations Engagement - Zentek attended a working session hosted by the Chiefs of Ontario, focusing on Indigenous consultation frameworks for mineral development in Ontario [1] - A working session with Constance Lake First Nation (CLFN) was held to advance collaboration, as the company prepares for environmental baseline studies and a new Preliminary Economic Assessment [1] - An existing implementation agreement with CLFN outlines governance, roles, responsibilities, and a framework for future project partnership [1] Albany Graphite Project - The Albany Graphite Project is located in Northern Ontario and is held through the company's subsidiary Albany Graphite Corp [1] - Independent testing confirmed Albany graphite achieves ultra-high purity of 99.9992% with a boron concentration of 2.60 ppm, suitable for nuclear-grade applications and lithium-ion battery anodes [1] - The project aims to become a North American source of critical-grade graphite for nuclear, battery, and defense supply chains [1] Company Overview - Zentek Ltd. is focused on developing and commercializing graphene-enabled and advanced material technologies across clean air, next-generation materials, and critical minerals [1] - The company's core platforms include Albany Graphite, ZenGUARD™, and Triera [1]

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of units, raising gross proceeds of $2,479,227 through the issuance of 2,338,893 units at a price of $1.06 per unit [1][2]. Group 1: Offering Details - Each unit consists of one common share, one-half of a Series A warrant, and one-half of a Series B warrant [2]. - The Series A warrant allows the holder to purchase one common share at $1.50 until October 22, 2027, with potential acceleration of the expiry date if the share price reaches $2.00 for 10 consecutive trading days [3]. - The Series B warrant allows the holder to purchase one common share at $2.00 until October 22, 2028, with potential acceleration if the share price reaches $3.00 for 10 consecutive trading days [4]. Group 2: Financial Aspects - The company paid finder fees totaling $35,429.33 and issued finder warrants for the purchase of 33,424 units at $1.06 per unit until October 22, 2027 [5]. - Proceeds from the offering will be utilized for general and administrative corporate purposes [6]. Group 3: Company Background - Zentek is an intellectual property development and commercialization company focused on enhancing product safety and efficiency through innovative technologies [11]. - The company’s patented ZenGUARD™ technology improves viral filtration efficiency for surgical masks and HVAC systems, with production facilities located in Guelph, Ontario [12].

Core Points - Zentek Ltd. has announced an increase in its non-brokered private placement to a total of up to $2,500,000, allowing for the issuance of up to 2,358,490 Units at a price of $1.06 per Unit [1] - The proceeds from the Offering will be utilized for working capital and general corporate purposes [1] Summary by Sections Offering Details - Each Unit consists of one Common Share, one-half of a Series A Warrant, and one-half of a Series B Warrant [2] - Series A Warrants allow the purchase of one Common Share at $1.50 for 24 months, with potential acceleration if the share price reaches $2.00 for 10 consecutive trading days [3] - Series B Warrants allow the purchase of one Common Share at $2.00 for 36 months, with potential acceleration if the share price reaches $3.00 for 10 consecutive trading days [4] Regulatory and Compliance - The closing of the Offering is subject to necessary corporate and regulatory approvals, including TSXV approval [5] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [5] Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products [7] - The company's patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8] - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University for diagnostic and therapeutic markets [10]

Core Viewpoint - Zentek Ltd. announces a non-brokered private placement to raise up to $2,000,000 through the issuance of units priced at $1.06 each, aimed at funding working capital and general corporate purposes [1]. Group 1: Private Placement Details - The offering will consist of up to 1,886,792 units, each unit comprising one common share, one-half of a Series A warrant, and one-half of a Series B warrant [2]. - Series A warrants allow the purchase of one common share at $1.50 for 24 months, with potential acceleration if the share price exceeds $2.00 for 10 consecutive trading days [3]. - Series B warrants permit the purchase of one common share at $2.00 for 36 months, with acceleration possible if the share price exceeds $3.00 for 10 consecutive trading days [4]. Group 2: Regulatory and Approval Information - The closing of the offering is contingent upon receiving necessary corporate and regulatory approvals, including from the TSX Venture Exchange [5]. - All securities issued will be subject to a four-month hold period from the date of issuance [5]. Group 3: Stock Options and Restricted Share Units - The company has granted stock options to certain officers, directors, and employees to acquire a total of 979,000 common shares at $1.06 per share, with a vesting schedule over five years [7]. - Additionally, 779,000 restricted share units have been granted, vesting on October 1, 2026 [7]. Group 4: Company Overview - Zentek is an intellectual property development and commercialization company focused on creating novel products that enhance the safety and efficiency of commercial partners' offerings [8][9]. - The company holds a global exclusive license for an Aptamer-based platform technology developed by McMaster University, targeting diagnostic and therapeutic markets [10].

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of debenture units, raising gross proceeds of $2,000,000 through the issuance of 2,000 debenture units [1] Group 1: Offering Details - Each debenture unit consists of $1,000 principal amount of 5% secured convertible debentures and 454 warrants to purchase common shares [2] - The convertible debentures will mature on April 9, 2028, and bear interest at a rate of 5% per annum, payable as a balloon payment on the maturity date [2] - The conversion price for the convertible debentures is set at $2.20 per common share, with the company having the option to force conversion if the trading price exceeds $4.40 [2] Group 2: Security and Warrants - The convertible debentures are secured by the company's interest in 521 mining claims held by its subsidiary Albany Graphite Corp., with a first ranking above all other creditors [3] - A total of 908,000 warrants were issued, each allowing the holder to purchase one common share at the conversion price until the maturity date [4] - The warrants will vest only upon the completion of a sale or transfer of the secured assets to a third party [4] Group 3: Use of Proceeds and Regulatory Approval - Net proceeds from the offering will be utilized for working capital and general corporate purposes [5] - The closing of the offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] Group 4: Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products [7] - The company's patented technology platform, ZenGUARD™, significantly increases bacterial and viral filtration efficiency for surgical masks and aims to enhance HVAC systems [9]

Core Viewpoint - Zentek Ltd. has announced an at-the-market offering agreement to raise up to US$30 million through the sale of common shares in the United States [1][4]. Group 1: Offering Details - The offering will be conducted through an "at-the-market offering" as defined under U.S. Securities Act, with sales made directly on Nasdaq or other recognized marketplaces [3]. - The offering will remain effective until the total gross sales reach US$30 million, unless terminated earlier by any party involved [4]. - Sales will occur at prevailing market prices, which may vary, and net proceeds will be used for corporate purposes as outlined in the Prospectus Supplement [4]. Group 2: Regulatory and Legal Framework - The common shares will be issued under a prospectus supplement dated March 3, 2025, as part of an existing U.S. registration statement [5]. - The offering is being made solely through the Prospectus Supplement, which has been filed with the SEC [5]. - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy securities in jurisdictions where such actions would be unlawful [6]. Group 3: Company Background - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on developing and commercializing innovative products [7]. - The company’s patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8]. - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University, aimed at diagnostic and therapeutic markets [9].